Amicus therapeutics, inc. (FOLD)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue:
Net product sales

60,525

55,293

48,768

44,130

34,046

32,644

20,596

21,309

16,696

14,729

10,874

7,158

4,169

-

2,127

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

6,552

6,945

5,596

5,367

4,055

4,344

4,310

3,135

2,615

2,610

1,790

1,061

775

-

344

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

293

475

456

39

-

0

0

5,477

6,114

3,970

4,138

2,380

4,306

Collaboration and milestone revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5,160

1,660

1,660

1,660

1,660

1,660

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

293

475

456

39

-

0

0

10,637

7,774

5,630

5,798

4,040

5,966

Gross profit

53,973

48,348

43,172

38,763

29,991

28,300

16,286

18,174

14,081

12,119

9,084

6,097

3,394

-

1,783

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

89,120

91,912

58,892

70,981

64,593

57,217

138,227

34,660

40,798

45,808

40,641

31,985

30,876

30,630

32,457

18,281

23,425

22,625

20,971

17,234

16,113

15,605

12,049

9,978

9,992

10,110

10,725

11,047

11,499

13,723

14,004

14,402

13,711

11,618

11,125

Selling, general, and administrative

40,215

43,300

39,680

42,578

44,303

38,765

31,867

29,172

27,396

28,581

21,647

19,311

19,132

18,681

17,469

19,300

15,701

17,192

15,372

8,278

6,427

5,518

5,270

4,753

5,176

4,635

4,830

4,455

4,995

5,819

4,095

3,917

4,841

6,720

4,402

Changes in fair value of contingent consideration payable

-931

-645

-789

-480

-1,383

-600

-1,300

-300

-1,100

-4,300

244,250

-1,050

-4,578

2,468

4,110

-10,186

-3,152

-1,977

-1,300

-100

-1,000

-900

600

-305

505

-

-

-

-

-

-

-

-

-

-

Loss on impairment of assets

-

-

-

-

-

-

-

-

-

-

465,427

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

1,764

1,514

1,116

1,154

991

1,201

1,073

973

969

1,107

851

812

823

906

896

767

673

577

395

353

508

364

375

396

412

429

450

421

422

442

420

341

380

426

438

Total operating expenses

132,030

137,371

100,477

115,193

111,270

97,783

172,467

65,105

70,263

79,796

284,316

53,158

55,409

47,749

46,723

48,542

43,001

41,391

38,045

26,943

24,058

21,998

17,109

14,741

16,077

15,174

16,005

15,923

16,916

19,984

18,519

18,660

18,932

18,764

15,965

Loss from operations

-78,057

-89,023

-57,305

-76,430

-81,279

-69,483

-156,181

-46,931

-56,182

-67,677

-275,232

-47,061

-52,015

-45,407

-44,940

-48,542

-43,001

-41,391

-38,045

-26,943

-24,058

-21,998

-16,816

-14,266

-15,621

-15,135

-16,005

-15,923

-16,916

-9,347

-10,745

-13,030

-13,134

-14,724

-9,999

Other income (expense):
Interest income

1,515

2,259

2,752

2,599

2,639

3,090

2,721

2,913

1,737

1,394

1,190

753

759

504

460

331

307

284

316

158

171

90

55

36

42

36

46

81

92

116

27

24

31

46

59

Interest expense

3,729

3,767

4,026

4,625

6,454

8,639

4,715

4,560

4,488

4,420

4,351

4,179

4,290

1,881

1,517

1,055

945

851

17

338

372

378

377

374

355

7

9

12

19

15

43

27

32

41

48

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

0

11

8

50

-28

7

26

10

11

15

-81

-8

-

-

-

-

-

-

-

-

-

-

Loss on exchange of convertible notes

0

0

0

-4,500

-36,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-952

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivatives

-

-

0

0

-

-39

0

-7,600

4,900

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-517

-619

-2,594

-553

118

2,376

-742

-3,376

-2,078

3,432

Other (expense) income

-8,316

646

-3,481

-877

1,086

-2,041

-1,039

-5,316

2,764

954

2,044

2,400

610

-1,594

-910

-2,237

-52

13

-54

-10

-29

-47

-11

-10

-9

-

-

-

-

21

-

0

0

0

70

Loss before income tax

-88,587

-89,885

-62,060

-83,834

-120,131

-77,073

-159,214

-61,494

-51,308

-69,749

-276,349

-48,087

-54,936

-61,680

-46,907

-51,503

-43,691

-

-37,800

-27,133

-

-

-

-

-

-

-

-13,260

-16,290

-9,343

-13,137

-12,291

-9,759

-12,641

-13,350

Income tax expense

361

-156

-251

717

168

1,010

-51

339

-1,392

-541

-164,683

49

56

-

-253

-453

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-88,948

-89,729

-61,809

-84,551

-120,299

-78,083

-159,163

-61,833

-49,916

-69,208

-111,666

-48,136

-54,992

-58,647

-46,654

-51,050

-43,691

-42,897

-37,800

-27,133

-24,288

-21,220

-17,149

-14,614

-15,943

-14,589

-15,349

-10,015

-16,290

-9,343

-13,137

-8,662

-9,759

-12,641

-13,350

Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)

-0.35

-0.32

-0.24

-0.36

-0.56

-0.43

-0.84

-0.33

-0.28

-0.43

-0.69

-0.34

-0.39

-0.41

-0.33

-0.40

-0.35

-0.36

-0.32

-0.27

-0.25

-0.24

-0.22

-0.22

-0.25

-0.29

-0.31

-0.19

-0.33

-0.20

-0.35

-0.24

-0.28

-0.37

-0.39

Weighted-average common shares outstanding - basic and diluted (in shares)

256,968

255,400

254,674

238,089

213,519

189,398

189,162

188,621

175,977

166,852

160,796

143,000

142,770

142,649

140,656

129,122

125,178

125,232

118,724

99,994

95,743

87,320

78,889

67,212

64,353

49,621

49,621

49,493

48,010

46,870

37,887

34,269

34,979

34,530

34,498